Aethlon Medical (NASDAQ:AEMD) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Aethlon Medical (NASDAQ:AEMD) in a report released on Sunday. The brokerage issued a sell rating on the medical equipment provider’s stock.

Separately, HC Wainwright reissued a “buy” rating and set a $7.00 target price on shares of Aethlon Medical in a report on Monday, March 10th.

Aethlon Medical Stock Performance

Shares of AEMD stock opened at $0.35 on Friday. The stock has a market capitalization of $5.63 million, a price-to-earnings ratio of -0.22 and a beta of 1.71. Aethlon Medical has a one year low of $0.24 and a one year high of $1.79. The company’s 50-day simple moving average is $0.46 and its 200-day simple moving average is $0.49.

Aethlon Medical (NASDAQ:AEMD) last issued its earnings results on Wednesday, February 12th. The medical equipment provider reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.09. As a group, research analysts forecast that Aethlon Medical will post -0.73 EPS for the current year.

Hedge Funds Weigh In On Aethlon Medical

Several institutional investors have recently made changes to their positions in AEMD. Renaissance Technologies LLC acquired a new position in Aethlon Medical during the 4th quarter valued at approximately $25,000. Allegiance Financial Group Advisory Services LLC bought a new position in shares of Aethlon Medical during the fourth quarter worth about $26,000. Sassicaia Capital Advisers LLC acquired a new stake in shares of Aethlon Medical in the 4th quarter worth about $31,000. Virtu Financial LLC bought a new stake in Aethlon Medical in the 4th quarter valued at about $81,000. Finally, Boothbay Fund Management LLC acquired a new position in Aethlon Medical during the 4th quarter valued at about $186,000. 1.99% of the stock is owned by institutional investors.

Aethlon Medical Company Profile

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.